	US 12,146,002 B2
	Polymer agonists of mu opioid receptors
Theodore E. Maione, Green Island, NY (US); James Hamsher, Darien, CT (US); and Constantine Basil Maglaris, Darien, CT (US)
Assigned to CYTOGEL PHARMA, LLC, Darien, CT (US)
Filed by CYTOGEL PHARMA, LLC, Darien, CT (US)
Filed on Apr. 20, 2022, as Appl. No. 17/724,913.
Application 17/724,913 is a continuation of application No. 16/609,840, previously published as PCT/US2018/061821, filed on Nov. 19, 2018.
Claims priority of provisional application 62/588,013, filed on Nov. 17, 2017.
Prior Publication US 2022/0251139 A1, Aug. 11, 2022
Int. Cl. C07K 7/06 (2006.01); A61K 38/00 (2006.01); A61K 47/54 (2017.01); A61K 47/60 (2017.01); A61K 47/61 (2017.01); A61K 47/62 (2017.01); C07K 5/107 (2006.01)

CPC C07K 7/06 (2013.01) [A61K 47/542 (2017.08); A61K 47/60 (2017.08); A61K 47/61 (2017.08); A61K 47/62 (2017.08); C07K 5/1016 (2013.01); A61K 38/00 (2013.01)]

13 Claims

1. A polymer having a sequence SEQ ID NO: 1: Tyr¹-Xaa²-Xaa³-Phe⁴or a salt thereof, wherein Xaa²is D-serine, D-threonine, D-glutamate, D-aspartate, D-glutamine, D-asparagine, D-arginine, or D-histidine, and

Xaa³is tryptophan,

wherein said polymer is not conjugated, and wherein said polymer is linear and the C-terminus of Phe⁴is modified with —NH₂.